

WHO issues guidelines for HepB treatment

March 13, 2015 | News | By BioSpectrum Bureau

WHO issues guidelines for HepB treatment



Singapore: WHO has issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year, most of them in low- and middle-income countries.

Effective medicines exist that can prevent people developing these conditions so they live longer. But most people who need these medicines are unable to access them or can only obtain substandard treatment. One reason for this is the lack of clear evidence-based guidance for countries (especially low- and middle-income countries) as to who should be treated and what medicines to use, WHO stated.

"Deciding who needs treatment for hepatitis B depends on a number of factors," says Dr Stefan Wiktor, program leader, WHO's Global Hepatitis Programme. "These new guidelines, which give treatment recommendations that rely on simple, inexpensive tests, will help clinicians make the right decisions."

The "WHO guidelines for the prevention, care and treatment of persons living with chronic hepatitis B infection" lay out a simplified approach to the care of people living with chronic hepatitis B, particularly in settings with limited resources.

Key recommendations include:

1. The use of a few simple non-invasive tests to assess the stage of liver disease to help identify who needs treatment;

prioritizing treatment for those with cirrhosis - the most advanced stage of liver disease;

2. The use of two safe and highly effective medicines, tenofovir or entecavir, for the treatment of chronic hepatitis B; and regular monitoring using simple tests for early detection of liver cancer, to assess whether treatment is working, and if treatment can be stopped.

Ã?Ã

3. The special needs of specific populations, such as people co-infected with HIV, as well as children and adolescents, and pregnant women are also considered.

The two recommended medicines are already available in many countries as generics, and thus are relatively inexpensive, costing as little as USD5 per person per month. "Because for so many people treatment is life-long it is important that patients can access these medicines at the lowest possible price" says Dr Wiktor.

A number of countries are beginning to develop hepatitis B treatment programmes, and the newly-released document also provide guidance on how to organize hepatitis care and treatment services. "For example, countries need to think about ways to improve access to medicines and how best to deliver quality care that builds on existing health services and staff," says Dr Philippa Easterbrook, from the WHO Global Hepatitis Programme.

Ã?Ã